CEO Gary Phillips said, "These new findings significantly enhance our understanding of scarring and the impact of topical pan-LOX inhibitors." …
Syntara’s topical anti-fibrotic drug leads to significant normalisation of skin in established scars
February 18, 2025 Australian BiotechBioPharma
Latest Video
New Stories
-
Syntara’s topical anti-fibrotic drug leads to significant normalisation of skin in established scars
February 18, 2025 - - Australian Biotech -
Trump suspends law that changed the industry's approach to public affairs
February 18, 2025 - - Latest News -
Pharmx Technologies partners with Toniq to expand pharmacy solutions in New Zealand
February 18, 2025 - - Latest News -
Pfizer teams up with Heart of Australia to expand access to GP education
February 18, 2025 - - Latest News -
HMRI partners with Novartis to supercharge heart health impact
February 17, 2025 - - Latest News -
PYC Therapeutics to raise up to $146 million to support late-stage trials
February 17, 2025 - - Australian Biotech -
Australia isn’t ready for the next cardiac epidemic, warns landmark heart valve disease report
February 17, 2025 - - Latest News